PUBLICATION

CPhI

AUTHORS

JP Stevenson, Alex Heeley

Turkey Pharma 2014 CPhI Pharmaceuticals Insights

May 03, 2014

Estimated to reach a value of $36 billion by 2023, Turkey’s pharmaceuticals manufacturing industry shows strong growth potential. Government support, high technological standards, and logistical advantages make Turkey an excellent place to manufacture and export pharmaceuticals. If the public and private sectors can collaborate to improve practices and profit margins, the country will become a global pharmaceuticals powerhouse.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

MACIG 2026 - Pre-Release

Africa has been attracting more diverse and innovative capital flows over recent years. The US, Europe, the Middle East, Japan, and even India are all crowding in, while China maintains its already well-established presence.

MORE PREVIOUSLY PUBLISHED

MACIG

"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."

SUBSCRIBE TO OUR NEWSLETTER